珀金埃尔默网站上的Cookie
珀金埃尔默使用cookies来确保我们为您提供在我们网站上的最佳体验。 这可能包括来自第三方网站的cookies。 如果您不改变您的设置点击继续,我们会认为您同意接收本网站的cookies。 您可以随时更改您的Cookie设置。 要了解更多信息,请查看我们的Cookie政策,其中包含有关如何管理Cookie的信息。

Innovators in Cancer Immunology: Colorectal Cancer

June 12, 2017

Innovators in Cancer Immunology: Colorectal Cancer

Skeleton

Jerome Galon, PhD
Director, Laboratory for Integrated Cancer Immunology
INSERM, Paris, France

To advance the understanding of disease mechanisms in cancer, it is critical that researchers see everything a tumor has to show them. Leveraging PerkinElmer’s Phenoptics Quantitative Pathology Research Solutions, researchers are now visualizing and measuring tumor cells and multiple immune-cell phenotypes simultaneously for the first time in formalin-fixed paraffin-embedded (FFPE) tissue.

Because of Phenoptics’ integration of multiplexed immunohistochemistry and imaging, leading scientists are now able to quantitatively capture systems biology data in cellular detail. What follows are brief profiles of some of these Innovators in Cancer Immunology and how they are using Phenoptics to discover new insights into the complexity of immune-cancer interactions that affect countless millions of patients around the world.

Dr. Jerome Galon’s laboratory aims to understand tumor progression and immune reaction against cancer by using integrative biology and bioinformatics to improve the therapeutic management of cancer patients. Dr. Galon and his associates hypothesize that integrative biology approaches will provide a better knowledge of the local interplay between immune components and tumor cells. Dr. Galon is known for discovering and developing the ‘Immunoscore’ for prognostic assessment of colorectal cancer. This was the first clear demonstration of the power of automation and cancer-immunology to stratify patients according to immune status and the likelihood of progression. He is now using Phenoptics to go beyond Immunoscore to explore higher multliplexed biomarkers to reveal deeper details about how cancer evades the immune system. Dr. Galen’s expectation is that the richer detail afforded by Phenoptics will lead to new treatable targets and better predictive tests for checkpoint inhibitors in colorectal cancer treatment.


更多故事关于 生命科学, 病理研究

Innovators in Cancer Immunology: Lymphoma

Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a lymphoma cancer case study, Dr. Rodig uses t...

Innovators in Cancer Immunology: Breast Cancer

Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a breast cancer case study, Dr. Rimm uses this...